Therapeutic pipeline for soft-tissue sarcoma

Introduction: Soft-tissue sarcomas (STS) represent a heterogeneous group of malignant tumors originating from connective tissues. Over recent years, this heterogeneity has led to a molecular breakdown of STS and subsequent use of targeted agents in several molecularly defined subgroups. After the in...

Full description

Saved in:

Bibliographic Details
Published in:	Expert opinion on pharmacotherapy Vol. 12; no. 16; pp. 2479 - 2491
Main Authors:	Cassier, Philippe A, Labidi-Galy, Sana Intidhar, Heudel, Pierre, Dutour, Aurélie, Méeus, Pierre, Chelghoum, Maria, Alberti, Laurent, Ray-Coquard, Isabelle, Blay, Jean-Yves
Format:	Journal Article
Language:	English
Published:	England Informa UK, Ltd 01.11.2011 Taylor & Francis
Subjects:	angiogenesis Angiogenesis Inhibitors Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents Antineoplastic Agents - therapeutic use Cancer Enzyme Inhibitors Enzyme Inhibitors - therapeutic use Humans Insulin-Like Growth Factor I Insulin-Like Growth Factor I - antagonists & inhibitors Insulin-Like Growth Factor II Insulin-Like Growth Factor II - antagonists & inhibitors Life Sciences molecularly targeted agent mTOR Oncogene Protein v-akt Oncogene Protein v-akt - antagonists & inhibitors Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases - antagonists & inhibitors Platelet-Derived Growth Factor Platelet-Derived Growth Factor - antagonists & inhibitors Protein-Tyrosine Kinases Protein-Tyrosine Kinases - antagonists & inhibitors Receptor, IGF Type 1 Receptor, IGF Type 1 - antagonists & inhibitors Sarcoma Sarcoma - drug therapy Soft Tissue Neoplasms Soft Tissue Neoplasms - drug therapy soft-tissue sarcoma TOR Serine-Threonine Kinases TOR Serine-Threonine Kinases - antagonists & inhibitors
ISSN:	1465-6566, 1744-7666, 1744-7666
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!